This double-digit growth in new drug sales showcases the company's ability to successfully commercialize cutting-edge ...

Biopharma executives make their predictions for the year ahead, from a bold forecast for the return of the megadeal to a plea ...

Bristol-Myers Squibb stock has rebounded strongly in 2024 ... When BMY completed its deal for Celgene in 2020, it inherited several multi-billion dollar selling drug products, such as >$12bn ...

Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on.

Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer's-related psychosis during the ...

Bristol Myers Squibb Co. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN) E3 ubiquitin ligase-binding moiety coupled to a DNA-binding protein Ikaros (IKZF1 ...

Analyst David Risinger of Leerink Partners reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target of $73.00. Discover outperforming stocks and invest ...

Bristol Myers Squibb CEO Chris Boerner described his company's new drug, Cobenfy, which can be used to treat psychiatric disorders like schizophrenia. He said the treatment is effective but doesn ...

Arsenal Biosciences, Inc., a clinical-stage programmable cell therapy company, announced Monday that drug maker Bristol-Myers Squibb ...

Bristol-Myers Squibb's recent struggles stem from concerns ... which it acquired as part of its 2019 deal for cancer specialist Celgene. However, the drugmaker's third-quarter 2024 results paint ...